Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status

被引:200
作者
Szulc, P
Hofbauer, LC
Heufelder, AE
Roth, S
Delmas, PD
机构
[1] Hop Edouard Herriot, INSERM U 403, F-69437 Lyon, France
[2] Univ Marburg, Div Gastroenterol Endocrinol & Metab, D-35033 Marburg, Germany
[3] Immunodiagnost, D-64625 Bensheim, Germany
关键词
D O I
10.1210/jc.86.7.3162
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Previous studies have suggested an important role for androgens and estrogens in bone metabolism in men. However, their local mode of action has not been clearly established. Osteoprotegerin (OPG) is a secreted decoy receptor that inhibits osteoclast formation and activity by neutralizing its cognate ligand. To assess the role of OPG on hone metabolism in men, me conducted a study aimed at evaluating OPG serum levels and their correlation with age, bone mineral density, biochemical markers of bone turnover, and testosterone and estradiol levels in 252 men, aged 19-85 yr. Serum concentrations of OPG increased significantly with age (r = 0.41; P = 0.0001), and were positively correlated with free testosterone index and free estradiol index (r = 0.20, P < 0.002 and r = 0.15; P < 0.03, respectively) after adjustment for age and body weight. Beyond the age of 40 yr, OPG serum concentrations were negatively correlated with urinary excretion of total deoxypyridinoline (r = -0.20; P < 0.01) and PTH serum levels (r = -0.23; P < 0.01). In contrast, there was no correlation with biochemical markers of bone formation, 25-hydroxyvitamin Dg levels, or bone mineral density at any site. Our data reveal that age as well as androgen and estrogen status are significant positive determinants, whereas PTH is a negative determinant, of OPG serum levels in men. These data suggest that OPG may be an important paracrine mediator of bone metabolism in elderly men and highlight the role of estrogens in the homeostasis of the male skeleton.
引用
收藏
页码:3162 / 3165
页数:4
相关论文
共 28 条
  • [1] Arrighi H, 2000, J BONE MINER RES, V15, pS538
  • [2] ARRIGHI HM, 1998, BONE S1, V23, pT411
  • [3] Bekker PJ, 1999, J BONE MINER RES, V14, pS180
  • [4] Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency
    Bilezikian, JP
    Morishima, A
    Bell, J
    Grumbach, MM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) : 599 - 603
  • [5] Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women
    Browner, WS
    Lui, LY
    Cummings, SR
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) : 631 - 637
  • [6] Effect of testosterone and estradiol in a man with aromatase deficiency
    Carani, C
    Qin, K
    Simoni, M
    FaustiniFustini, M
    Serpente, S
    Boyd, J
    Korach, KS
    Simpson, ER
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (02) : 91 - 95
  • [7] Prevalence of vitamin D insufficiency in an adult normal population
    Chapuy, MC
    Preziosi, P
    Maamer, M
    Arnaud, S
    Galan, P
    Hercberg, S
    Meunier, PJ
    [J]. OSTEOPOROSIS INTERNATIONAL, 1997, 7 (05) : 439 - 443
  • [8] Fraher LJ, 2000, J BONE MINER RES, V15, pS441
  • [9] Androgen effects on bone metabolism: recent progress and controversies
    Hofbauer, LC
    Khosla, S
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 140 (04) : 271 - 286
  • [10] The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases
    Hofbauer, LC
    Heufelder, AE
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (07) : 2355 - 2363